Market Cap
$92.4B
HCA
HCA Healthcare, Inc.
$428.58 ▲ +1.23%
Prev close $423.39Market cap$92.4B
ConsensusHold
12-mo target$454.23 (+6.2%)
▲ Bullish
Analyst conviction 6/10
Insider Selling Cluster (4 insiders)31 New Institutional Positions19 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on HCA right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Buy (57%)
Inst. Holders
50 funds
Inst. Value
$37.6B
Inst. Activity
31 buys / 19 sells
Insider Activity
$0.00 buy / $15.7M sell
Insider Net $
-$15.7M
Social Sentiment
73° Bullish
SEC Reports
8
Congressional
3 trades
Price chart 30d +6.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc. - HCA
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Aug 26, 2026 Insider
Jul 24, 2026 SEC McAlevey Michael R disposed of 7,769 shares
EVP & Chief Legal & Admin Off. @ $429.00 ($3.3M)
HCA Healthcare reported Q2 2026 results consistent with its July 14 preview: revenue of $20.230B (+8.7% YoY) and GAAP EP
8-K — Impact 5/10
HCA Healthcare issued preliminary Q2 2026 results and revised 2026 guidance downward. Q2 revenue grew 8.7% YoY to ~$20.2
8-K — Impact 6/10
Jun 30, 2026 Inst.
NORGES BANK — NEW
2,145,367 shares ($836.5M)
Jun 30, 2026 Inst.
Capital International Investors — TRIM
1,916,947 shares ($747.4M)
Jun 30, 2026 Congress
Jun 18, 2026 SEC William Keating buy
$15,001 - $50,000 — House
HCA Healthcare announced that Dr. Michael Cuffe will step down as Executive Vice President and Chief Clinical Officer ef
8-K — Impact 2/10
Analyst ratings buy % -1.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
57% rate it Buy or better · 30 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | BMO Capital | INITIATE | Outperform | 53% |
| Sep 18, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
| Sep 8, 2026 | RBC Capital | REITERATE | Outperform | 55% |
| Aug 20, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Aug 3, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Jul 28, 2026 | Goldman Sachs | MAINTAIN | Buy | 54% |
| Jul 28, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 27, 2026 | UBS | MAINTAIN | Buy | 55% |
| Jul 27, 2026 | Morgan Stanley | MAINTAIN | Underweight | 55% |
| Jul 27, 2026 | RBC Capital | REITERATE | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 11 | 12 | 1 | 0 | 57% | |
| Aug 1, 2026 | 6 | 11 | 12 | 1 | 0 | 57% | |
| Jul 1, 2026 | 6 | 13 | 10 | 1 | 0 | 63% | |
| Jun 1, 2026 | 6 | 13 | 10 | 1 | 0 | 63% | |
| May 1, 2026 | 6 | 13 | 10 | 1 | 0 | 63% | |
| Apr 1, 2026 | 6 | 12 | 12 | 1 | 0 | 58% | |
| Mar 1, 2026 | 6 | 12 | 12 | 1 | 0 | 58% | |
| Feb 1, 2026 | 6 | 12 | 12 | 1 | 0 | 58% |
Price targets
Where 22 covering analysts think HCA trades over the next 12 months.
$454.23 +6.2% upside Buy
Current$427.65 Low$380.00 Median$450.00 High$579.00 22 analysts
$380.00$579.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Social media sentiment mood +50.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
73°
Bullish
BearishNeutralBullish
Recent posts
Rate this portfolio construction plan, what am I missing?
▲ 1 · 💬 0· ⚡ 0.5
Key new client for a name that doesn’t reflect the positives - OM Outset Medical
▲ 1 · 💬 0· ⚡ 0.5
I finally rest and watch the sunrise on a grateful universe
▲ 1 · 💬 1· ⚡ 0.5
I finally rest and watch the sunrise on a grateful universe
▲ 1 · 💬 1· ⚡ 0.5
HCA Healthcare Q1 Earnings Call Live Transcript
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 0 bullish, 1 bearish, 1 mixed, 6 neutral · avg impact 3.4/10.
MIXED8-K5/10
HCA Healthcare reported Q2 2026 results consistent with its July 14 preview: revenue of $20.230B (+8
Jul 24, 2026
BEARISH8-K6/10
HCA Healthcare issued preliminary Q2 2026 results and revised 2026 guidance downward. Q2 revenue gre
Jul 14, 2026
NEUTRAL8-K2/10
HCA Healthcare announced that Dr. Michael Cuffe will step down as Executive Vice President and Chief
Jun 18, 2026
NEUTRALCOURT-RULING1/10
A pro se plaintiff's EMTALA claim against Wilson Medical Center, HCA Florida Kendall Hospital, and o
May 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA Healthcare, Inc. - HCA
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company")
Sep 18, 2026
short_volume
Short Volume: HCA — 72.0% short (0.4M / 0.5M)
Short: 371,778 | Exempt: 0 | TRF Vol: 516,447 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
Sep 11, 2026
short_volume
Short Volume: HCA — 75.6% short (0.4M / 0.6M)
Short: 435,773 | Exempt: 0 | TRF Vol: 576,425 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: HCA — 78.9% short (0.7M / 0.9M)
Short: 692,715 | Exempt: 235 | TRF Vol: 878,497 | Short Ratio: 78.9% | Off-exchange volume (dark pool + OTC)
Sep 8, 2026
short_volume
Short Volume: HCA — 79.4% short (0.5M / 0.6M)
Short: 502,989 | Exempt: 85 | TRF Vol: 633,165 | Short Ratio: 79.4% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $6.66 | $5.83–$7.35 | -4.3% | -1.2% | 0↑ 2↓ | $19.4B | 20 |
| Next Q | $8.05 | $7.57–$8.61 | 0.5% | +1.0% | 1↑ 1↓ | $19.9B | 20 |
| Current FY | $29.49 | $28.62–$30.41 | 4.5% | -0.0% | 0↑ 3↓ | $78.5B | 23 |
| Next FY | $32.02 | $30.16–$34.04 | 8.6% | -0.3% | 1↑ 3↓ | $81.6B | 23 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $6.659 | — |
| 7d ago | $6.685 | -0.026 |
| 30d ago | $6.737 | -0.078 |
| 60d ago | $6.777 | -0.118 |
| 90d ago | $7.273 | -0.614 |
Institutional ownership
Which big funds own HCA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $37.6B total value (96,386,021 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, Sanders. Net buying activity: 31 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 13,003,600 | $5.1B | 13.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 10,141,708 | $4.0B | 10.5% | — |
| Sanders Capital, LLC | 8,828,287 | $3.4B | 9.2% | — |
| STATE STREET CORP | 7,469,035 | $2.9B | 7.7% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 4,707,473 | $1.8B | 4.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,668,008 | $1.4B | 3.8% | — |
| First Eagle Investment Management, LLC | 3,295,565 | $1.3B | 3.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,712,828 | $1.1B | 2.8% | — |
| MORGAN STANLEY | 2,586,771 | $1.0B | 2.7% | — |
| GOLDMAN SACHS GROUP INC | 2,464,314 | $960.8M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 2,145,367 | — | $836.5M |
| Capital International Investors | TRIM | 3,033,612 | 1,916,947 | -36.8% | $747.4M |
| FMR LLC | TRIM | 4,401,023 | 1,632,520 | -62.9% | $636.5M |
| Darsana Capital Partners LP | ADD | 750,000 | 1,100,000 | +46.7% | $428.9M |
| Life Cycle Investment Partners Ltd | ADD | 694,200 | 912,404 | +31.4% | $355.7M |
| Nuveen, LLC | TRIM | 783,548 | 511,927 | -34.7% | $199.6M |
| AustralianSuper Pty Ltd | ADD | 225,950 | 409,438 | +81.2% | $159.6M |
| HSBC HOLDINGS PLC | ADD | 309,467 | 406,750 | +31.4% | $158.6M |
| Amundi | TRIM | 615,094 | 358,177 | -41.8% | $139.6M |
| ALLIANCEBERNSTEIN L.P. | TRIM | 426,757 | 284,126 | -33.4% | $134.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
19 insiders, 50 transactions. Net -$15.7M — $0.00 bought, $15.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | McAlevey Michael R | EVP & Chief Legal & Admin Off. | J | 7,769 | $429.00 | $3.3M |
| May 7, 2026 | Marks Mike A | EVP and CFO | GIFT | 3,336 | — | — |
| Apr 28, 2026 | Riley Wayne Joseph | Director | AWARD | 509 | — | — |
| Apr 28, 2026 | Smith Andrea B | Director | AWARD | 509 | — | — |
| Apr 28, 2026 | FRIST THOMAS F III | Director | AWARD | 1,041 | — | — |
| Apr 28, 2026 | Frist William R | Director | AWARD | 809 | — | — |
| Apr 28, 2026 | CHIDSEY JOHN | Director | AWARD | 809 | — | — |
| Apr 28, 2026 | DEPARLE NANCY ANN | Director | AWARD | 509 | — | — |
| Apr 28, 2026 | MICHELSON MICHAEL W | Director | AWARD | 925 | — | — |
| Feb 11, 2026 | Berres Jennifer | SVP & Chief Human Res. Officer | SELL | 4,010 | $503.00 | $2.0M |
Congressional trades
HCA trades disclosed by members of Congress, with disclosure delay.
2 members · 3 buys / 0 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | William Keating | D | HOUSE | BUY | $15,001 - $50,000 | HCA Healthcare Inc | Aug 14, 2026(46d) |
| Jun 17, 2026 | Jared Moskowitz | D | HOUSE | BUY | $1,001 - $15,000 | HCA Healthcare Inc | Jul 27, 2026(41d) |
| Jun 17, 2026 | Jared Moskowitz | D | HOUSE | BUY | $1,001 - $15,000 | HCA Healthcare Inc | Jul 27, 2026(41d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for HCA.
Shares short
6,479,985
Settlement Sep 15, 2026
Change vs prior
+5.6%
Semi-monthly cycle
Days to cover
4.5
At avg daily volume
Of shares outstanding
≈3.0%
Estimate — not % of float
All HCA filing & press-release reports (8)
- 8-K reportJul 24, 2026
- 8-K reportJul 14, 2026
- 8-K reportJun 18, 2026
- COURT-RULING reportMay 28, 2026
- 8-K reportApr 27, 2026
- 8-K reportApr 24, 2026
- DEFA14A reportMar 13, 2026
- 8-K reportFeb 25, 2026